Premium
Gynecomastia with sulpiride
Author(s) -
Kaneda Y.,
Fujii A.
Publication year - 2002
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1046/j.1365-2710.2002.00378.x
Subject(s) - sulpiride , gynecomastia , prolactin , medicine , galactorrhea , benzamide , dopaminergic , endocrinology , testosterone (patch) , dopamine , hormone , chemistry , organic chemistry
Objective: Neuroleptic agents have been associated with gynecomastia, but evidence for a causal link is insufficient. We describe a case of unilateral gynecomastia without galactorrhea in a 38‐year‐old man during sulpiride treatment for generalized anxiety disorder. The patient had been treated with sulpiride (100 mg/day) for about 5 months by a primary care physician. In this patient, no specific endocrine alterations were found, except for a marked increase in prolactin (PRL) level and slight decrease in testosterone (T)/estradiol (E 2 ) ratio. Drug withdrawal led to a reduction of the lump. Sulpiride is a substituted benzamide with selective dopaminergic blocking activity. From the marked increase in PRL level and the slight decrease in T/E 2 ratio observed during sulpiride therapy, it is proposed that sulpiride may induce gynecomastia by inhibiting hypothalamic‐pituitary function directly, and/or indirectly through hyperPRLemia.